Ablation Lesion Assessment Patents: Who Leads, Where the Gaps Are 2026
Ablation Lesion Assessment Patents: Filing Trends and Ownership Concentration
39.5% of all filings sit with just five assignees, out of 1,685 records in scope — a tight core around force-time-integral and lesion-index claims. Annual filings climbed from 94 in 2017 to a peak of 96 in 2021, then fell to 34 by 2024 — a 65% drop over that three-year span. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are still incomplete and should not be read as a continuation of the decline.
- 1ST JUDE MEDICAL ATRIAL FIBRILLATION DIVISION INC211
- 2BIOSENSE WEBSTER (ISRAEL) LTD182
- 3MEDTRONIC INC102
- 4MEDTRONIC IRELAND MFG UNLIMITED CO91
- 5MEDTRONIC CRYOCATH LP80
See the full ablation lesion assessment analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on ablation lesion assessment patents
What counts as an ablation lesion assessment patent?
These are patents covering the methods and instrumentation used to determine whether a cardiac ablation lesion is complete and durable, including force-time integral measurement, tissue temperature sensing, gap detection between ablation points, acute reconnection testing, and imaging-based confirmation. The dataset behind this page uses a search string combining these lesion-assessment terms with ablation and lesion-index language, covering 1,685 published records from 2015 through mid-2026. It spans both device hardware claims and the software or signal-processing methods used to interpret sensor data during and after ablation.
Who are the leading patent holders in ablation lesion assessment?
Ownership is concentrated: the top five assignees together hold 39.5% of the 1,685 records in scope, and the top ten hold 55.3%. The leading assignee alone holds 211 records, well ahead of the fifth-place holder at 80 and tenth place at 39. Behind that top tier sits a long tail of organisations with only a handful of filings each, which is typical of a field with a few dominant device platforms.
Is the number of ablation lesion assessment patent filings growing or shrinking?
Filings rose from 94 in 2017 to a peak of 96 in 2021, then declined to 34 by 2024, a 65% drop over that three-year window. 2024 is the most recent year that can be read as a complete count, because publication typically lags filing by around 18 months, so 2025 and 2026 figures will fill in later and should not yet be read as a continued decline. The pullback from the 2021 peak is more consistent with saturated claim space among leading filers than with a shrinking technology area.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Ablation Lesion Assessment covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.